Product Details
| Product Name:
MSU-42011 |
CAS No.:
2456434-36-7 |
| Purity:
99.52% |
Supply Ability:
10g |
| Release date:
2025/11/10 |
Product Introduction
Bioactivity
| Name | MSU-42011 |
| Description | MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist. It potently inhibits the expression of iNOS, low SREBP-induced and activated RXR, and p-ERK at the protein level. MSU-42011 has demonstrated antitumor activity in a [kras]-driven mouse model of lung cancer and is effective for the treatment of preclinical [kras]-driven lung cancer with immunomodulatory activity. |
| In vitro | MSU-42011 (300 nM; 8 h) showed a low induction effect on SREBP in HepG2 cells.[1]
MSU-42011 (0-5000 nM; 24 h) can activate RXR in HepG2 cells.[1] |
| In vivo | MSU-42011 (25 mg/kg; oral; for 12 weeks) significantly reduced the number, size, and overall tumor burden of tumors in the A/J mouse lung cancer model. Compared with the control group, there were fewer cells with active proliferation and showed a significant decrease in p-ERK [1].
MSU-42011 (25 mg/kg; oral; single dose) is most effective in reducing the number, size, and overall tumor burden of the A/J mouse lung cancer model in combination with C/P. Reduced macrophages in the lungs and increased activation markers of CD8+T cells [1].
MSU42011 (100 mg/kg; PO; single dose) reduces tumor burden in a mouse lung tumor model [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (117.63 mM), Sonication is recommended.
|
| Keywords | SREBP | RXR | RetinoidReceptor | Retinoid Receptor | PERK | NOSynthase | NO Synthase | MSU-42011 | MSU42011 | MSU 42011 | Inos | 6((3,5ditertbutylphenyl)(isobutyl)amino)nicotinicacid |
| Inhibitors Related | Isotretinoin | 2-Isopropyl-1H-imidazole | RMC-9805 | L-NAME hydrochloride | Chondroitin sulfate | Aminopicoline | RMC-6236 | 3-AMINO-1,2,4-TRIAZINE | L-Arginine | Benzil | Ethyl cinnamate | Diallyl disulfide |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Neuroprotective Compound Library | Lipid Metabolism Compound Library | Orally Active Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2068806-31-3
$90.00 / 1mg
-
CAS:1272353-82-8
$259.00 / 1mg
-
CAS:2095849-04-8
$95.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$66.00/1EA |
|
Amikon Limited
|
2018-12-26 |
United States